(Corrects day in paragraph 1 to Tuesday, not Wednesday, and dateline to Copenhagen) COPENHAGEN, Feb 3 (Reuters) – Danish drug maker Novo Nordisk said on Tuesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy. The maker of weight-loss drug Wegovy said in a statement that […]
Health
Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business
Audio By Carbonatix
(Corrects day in paragraph 1 to Tuesday, not Wednesday, and dateline to Copenhagen)
COPENHAGEN, Feb 3 (Reuters) – Danish drug maker Novo Nordisk said on Tuesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy.
The maker of weight-loss drug Wegovy said in a statement that Millar would take on the job on February 5, succeeding Dave Moore, and that Hong would start on February 15, replacing Ludovic Helfgott.
Before joining Novo Nordisk, Jamey worked for UnitedHealth Group, as CEO of Optum Specialty Holdings, while Hong joins Novo Nordisk from Merck Healthcare in Germany, it said.
(Reporting by Louise Rasmussen, editing by Anna Ringstrom)